The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy-Reference-Cited by-同舟云学术

The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy

Published:2006-04-24 Issue:7 Volume:20 Page:1069-1071
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Hoefnagel Jolanda GM,van der Lee Manon J,Koopmans Peter P,Schuurman Rob,Jurriaans Suzanne,van Sighem Ard I,Gras Luuk,de Wolf Frank,Galama Jochem MD,Burger David M

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference10 articles.

1. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients;Hsu;Antimicrob Agents Chemother,2003

2. Genotypic inhibitory quotient as predictor of virological response to ritonavir–amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients;Marcelin;Antimicrob Agents Chemother,2003

3. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient;Gonzalez;AIDS Res Hum Retroviruses,2004

4. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study);Breilh;AIDS,2004

5. Drug resistance mutations in HIV-1;Johnson;Top HIV Med,2003

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV;Therapeutic Drug Monitoring;2019-08

2. Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective;Future Virology;2013-09

3. Therapeutic Drug Monitoring of Antiretroviral Drugs in the Management of Human Immunodeficiency Virus Infection;Therapeutic Drug Monitoring;2012

4. A Randomized Clinical Trial Evaluating Therapeutic Drug Monitoring (TDM) for Protease Inhibitor–Based Regimens in Antiretroviral-Experienced HIV-Infected Individuals: Week 48 Results of the A5146 Study;HIV Clinical Trials;2011-08

5. Niveau de preuve du suivi thérapeutique pharmacologique du lopinavir;Therapies;2011-05